EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody

Muhamed Baljevic iD, Peter Voorhees, Cesar Rodriguez iD, Anita D'Souza iD, Alfred Chung iD, Eben Isaac Lichtman, Hana Safah, Katja C Weisel, Ravi Vij, Hira Mian, Hila Magen, Emma Searle iD und 11 weitere

Blood Journal · 16.11.2026

DOI: 10.1182/blood.2026034590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Journal, online erschienen am 16.11.2026. Verfasst von Muhamed Baljevic und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Etentamig is an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, composed of a low-affinity CD3 binding domain, potentially reducing cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding supporting monthly (Q4W) dosing after a single step-up dose (SUD). We report long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). In phase 1, patients received etentamig 60 mg Q4W or 40 mg Q3W, and in phase 1b, a SUD on Day 1 and 60 mg Q4W on Day 4. Among 146 patients (median age: 68 years; median [range] prior LoT: 4 [3-23]), median follow-up was 13 months (range: 1-48). Objective responses and ≥ very good partial responses occurred in 66% and 54% of patients. Median duration of response and progression-free survival were not reached. Pooled data suggest etentamig has a manageable safety profile, with Grade 3/4 neutropenia and infection occurring in 38% and 23% of patients. In phase 1b Arm A (n=23), overall CRS incidence was 30% (26% Grade 1; 4% Grade 2) with modified dexamethasone premedication and 1 SUD; median onset was 22.3 hours (range: 5.5-29.6) hours, with resolution in 20.7 hours (range: 1.8-131.7). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.

Autor:innen und Institutionen

  • University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
  • Atrium Health / Levine Center Institute, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States.
  • Mount Sinai, New York, NY, United States.
  • Froedtert & Medical College of Wisconsin Cancer Center, Milwaukee, WI, United States.
  • University of California San Francisco, San Francisco, California, United States.
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States.

ORCID-Profile: Muhamed Baljevic, Cesar Rodriguez, Anita D'Souza, Alfred Chung, Emma Searle, Neha S Korde, Saurabh Chhabra, Valerie Robinson, Shaji K Kumar

Zitieren

APA

Baljevic, M., Voorhees, P., Rodriguez, C., D'Souza, A., Chung, A., Lichtman, E. I., Safah, H., Weisel, K. C., Vij, R., Mian, H., Magen, H., Searle, E., Mckay, J. T., Korde, N. S., Chhabra, S., Svensson, A., Pothacamury, R. K., Talati, C., Allendorf, C., …, & Kumar, S. K. (2026). Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody. Blood Journal. https://doi.org/10.1182/blood.2026034590

Vancouver

Baljevic M, Voorhees P, Rodriguez C, D'Souza A, Chung A, Lichtman EI, et al. Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody. Blood Journal. 2026. doi:10.1182/blood.2026034590

BibTeX
@article{Baljevic2026,
  author = {Baljevic, Muhamed and Voorhees, Peter and Rodriguez, Cesar and D'Souza, Anita and Chung, Alfred and Lichtman, Eben Isaac and Safah, Hana and Weisel, Katja C and Vij, Ravi and Mian, Hira and Magen, Hila and Searle, Emma and Mckay, John T and Korde, Neha S and Chhabra, Saurabh and Svensson, Anders and Pothacamury, Rajvineeth Kumar and Talati, Chetasi and Allendorf, Carli and Hecquet, Claudie and Robinson, Valerie and Ahsan, Aarif and Kumar, Shaji K},
  title = {Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody},
  journal = {Blood Journal},
  year = {2026},
  doi = {10.1182/blood.2026034590}
}
Kostenlos starten →